HEALING Response Act of 2023

Hozzl · 2024-02-05T14:30:09Z

Explore the details of House Bill 3703 HEALING Response Act of 2023 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

2/5/2024, 2:30 PM

Summary of Bill HR 3703

The HEALING Response Act of 2023, also known as Bill 118 hr 3703, is a piece of legislation introduced in the US Congress aimed at addressing the mental health crisis in the country. The bill focuses on providing resources and support for individuals struggling with mental health issues, as well as improving access to mental health services.

One key aspect of the HEALING Response Act is the establishment of a national mental health hotline, which would provide 24/7 support and resources for individuals in crisis. This hotline would be staffed by trained professionals who can offer immediate assistance and referrals to mental health services.

Additionally, the bill includes provisions for expanding mental health services in schools and communities, with a focus on early intervention and prevention. This includes funding for mental health education programs, training for school staff, and increased access to mental health professionals in underserved areas. The HEALING Response Act also addresses the issue of mental health parity, ensuring that insurance companies cover mental health services at the same level as physical health services. This is aimed at reducing barriers to accessing mental health care and ensuring that individuals receive the treatment they need. Overall, the HEALING Response Act of 2023 seeks to improve mental health outcomes for individuals across the country by increasing access to services, providing support in times of crisis, and promoting mental health education and awareness.

Congressional Summary of HR 3703

Helping Evaluate Appropriate Logistical Infrastructure for National Government Response Act of 2023 or the HEALING Response Act of 2023

This bill requires the Government Accountability Office to review efforts undertaken by the Department of Health and Human Services to ensure that the United States has the capacity to rapidly produce medical countermeasures. (Medical countermeasures are certain medical products that may be used to diagnose, prevent, or treat conditions associated with chemical, biological, radiological, or nuclear threats or emerging infectious diseases during public health emergencies.)

The review must address, among other topics, efforts to transition to new initiatives for facilitating the development and manufacturing of countermeasures (e.g., transitioning from the Centers for Innovation and Advanced Drug Manufacturing program to Industrial Base Expansion Connect).

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 3703

Bill HR 3703 is currently in the status of Bill Introduced since May 25, 2023. Bill HR 3703 was introduced during Congress 118 and was introduced to the House on May 25, 2023. Bill HR 3703's most recent activity was Referred to the Subcommittee on Health. as of May 26, 2023

Bipartisan Support of Bill HR 3703

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 3703

Primary Policy Focus

Health

Potential Impact Areas

- Congressional oversight

- Government studies and investigations

- Health technology, devices, supplies

- Prescription drugs

Alternate Title(s) of Bill HR 3703

HEALING Response Act of 2023

Helping Evaluate Appropriate Logistical Infrastructure for National Government Response Act of 2023

To direct the Comptroller General of the United States to conduct and complete a review examining the efforts of the Secretary of Health and Human Services to ensure that the United States is prepared to rapidly produce certain medical countermeasures in the event of a public health emergency, and for other purposes.